Breast Cancer Clinical Trial
Official title:
A Multicenter, Randomized, Comparative Study Regarding the Efficacy of Denosumab on Normal Bone Mineral Density in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer (ENDEAVOR Trial)
Verified date | October 2023 |
Source | Kyoto Prefectural University of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD. Investigators will compare the inhibitory effects of denosumab on bone loss between participants with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy for stage I-IIIA postmenopausal hormone-sensitive breast cancer and controls.
Status | Active, not recruiting |
Enrollment | 160 |
Est. completion date | December 2027 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: Patients must meet all of the following items at the time of case registration: 1. Patients with infiltrative breast cancer, aged =20 years, meeting the following definitions: - Those pathologically diagnosed with stage I, II, or IIIA breast cancer (Cancer Management Regulations, 11th version) - Those who underwent appropriate surgery, such as mastectomy and breast-preserving surgery 2. Estrogen receptor (ER)- or progesterone receptor (PgR)-positive patients on immunohistochemical (IHC) staining 3. Females meeting one of the following criteria for menopause: - Those, aged =55 years, without menstruation - Those, aged <55 years, with amenorrhea for =12 months, or those diagnosed with menopause by attending physicians based on the FSH and estradiol levels - Those who underwent bilateral oophorectomy 4. Patients in whom the BMD for the lumbar vertebrae (L1-L4) on DXA before the start of this study is =-1.0SD of the mean value of young adult females (YAM), and the BMD for the femoral neck is =-1.0SD of YAM 5. Patients without lumbar vertebral or femoral fracture 6. Those with an ECOG PS of 0-2 7. Those with adequate organ functions (laboratory data within 4 weeks before case registration) - Leukocyte count, =3,000/mm3 or Neutrophil count, =1,500/mm3 - AST, ALT, =1.5-fold of the upper limit of the institutional reference range - Serum creatinine, =1.5-fold of the upper limit of the institutional reference range 8. Case registration should be performed before the following point:Twelve weeks after the completion of surgery or postoperative chemotherapy (The completion of chemotherapy refers to the completion of the final course, involving the recovery phase.) 9. Patients with an interval of =4 weeks after the discontinuation of therapy with bisphosphonates (oral preparations), estrogen preparations, raloxifene, calcitonin preparations, vitamin K preparations, active vitamin D preparations, or ipriflavone preparations, which influence bones 10. Those from whom written informed consent regarding study participation was obtained Exclusion Criteria: Whether each patient meets any of the following items must be checked on case registration: 1. Patients in whom distant metastasis was confirmed clinically or using imaging procedures at the time of case registration 2. Those with bilateral breast cancer 3. Those for whom postoperative hormonal therapy was started before consenting to study participation 4. Those who received endocrine therapy within 52 weeks before consenting to study participation 5. Those to whom bisphosphonate preparations were intravenously administered within 52 weeks before consenting to study participation 6. Those with the following diseases that may affect DXA - Severe scoliosis, immobility, hyperostosis or osteosclerosis of the lumbar vertebrae, calcification of the abdominal aorta, and vertebral disease 7. Those with a history of malignant tumors other than breast cancer within 260 weeks before consenting to study participation 8. Those with dental diseases, such as infectious diseases of the teeth or jaw and tooth trauma. Those for whom tooth or jaw surgery is scheduled within 6 weeks after consenting to study participation (tooth extraction, implantation) 9. Others who are considered to be ineligible by the chief investigator |
Country | Name | City | State |
---|---|---|---|
Japan | Hisako Ono | Kyoto |
Lead Sponsor | Collaborator |
---|---|
Kyoto Prefectural University of Medicine |
Japan,
Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | percentage change in the bone mineral density (BMD) for the lumbar vertebrae (L1-L4) on dual-energy X-ray absorptiometry (DXA) | The change is a value obtained by subtracting 1 from the BMD after 12 months/baseline BMD is expressed as a percentage | 12 months after the start of this study | |
Secondary | percentage change in the BMD for the lumbar vertebrae (L1-L4) on DXA | percentage change in the BMD for the femoral neck: After 2/3/4/5 years | after 2, 3, 4, and 5 years | |
Secondary | percentage change in the BMD for the femoral neck | percentage change in the BMD for the femoral neck: After 12 months and 2/3/4/5 years | after 12 months and 2/3/4/5 years | |
Secondary | percentage change in the BMD for the radius (an ultrasonic bone densimeter is used)institutions in which ultrasonic bone densimeters are used) | percentage change in the BMD for the radius (an ultrasonic bone densimeter is used): After 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only institutions in which ultrasonic bone densimeters are used) | after 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only | |
Secondary | Changes in Ca and bone metabolism markers | Changes in Ca (mg/dL corrected by albumin level) and bone metabolism markers such as TRAP5b, bone-specific alkaline phosphatase (BSAP), blood pentosidine) by blood sampling at every 6 months | after 24 weeks | |
Secondary | Appearance rate of morbid fracture in all participants | Appearance rate of morbid fracture up to 3 years in all participants. Morbid fractures include all types of fractures. | up to 3 years | |
Secondary | Disease-free survival | Disease-free survival at the end of the study | at least 5 year | |
Secondary | Overall survival | Overall survival at the end of the study | at least 5 year | |
Secondary | Appearance of adverse events | Appearance rate of adverse events (such as hypocalcemia and necrosis of the jaw) | at least 5 year | |
Secondary | Quality of life (QOL) | Quality of life(QOL), Japanese version Euro-Qol (EQ-5D-5L) evaluated by questionnaire at every 6 months | after 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |